Helping Address Drug Shortages in America
We’ve invested nearly $1 billion in pharmaceutical production facilities and distribution centers throughout the U.S.
Since 2017, Fresenius Kabi has invested nearly $1 billion to modernize and expand our advanced U.S. pharmaceutical production and distribution facilities. We are dedicated to strengthening the supply chain of care in and for the U.S. We have built a reputation as a trusted partner that can rapidly increase production levels in times of crisis and shortage.
We have been investing and taking action to create More Supply in America – building more filling and finishing capacity, agility, and redundancy to assure both speed and reliability of supply.
John Ducker, President and CEO of Fresenius Kabi USA, details the many ways in which Fresenius Kabi is expanding our capacity and capabilities in the U.S. to better serve our customers.
We delivered over 900 million units of injectable medicines in the past two years to U.S. hospitals and other sites of care.1 Our continued investments will allow us to nearly double U.S. production over the next five years. We are also building redundancies into our U.S. manufacturing and supply network to enable even more flexibility and resilience to react to future market needs.
Senior Vice President Brian Bulgarelli introduces the expansive capabilities of Fresenius Kabi’s three new built-to-suit distribution centers in the U.S.
Nearly $100 Million U.S. Supply Chain Expansion
This capacity expansion can help us more rapidly adapt to shifting customer needs. It helped us ramp up production of critical injectable medicines used by hospitals during the pandemic and enabled us to support America’s strategic national stockpile – as well as supporting America’s vaccine developers with vital pharmaceuticals.
2. 2023 Data on file.
